Study reveals how a new IgE antibody therapy reactivates immune cells, offering a promising approach to fighting ovarian ...

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces that it has completed the acquisition of TigaTx, Inc., a biotechnology company ...

Epsilogen has acquired antibody developer TigaTx in a deal that collates work from the companies’ alternative antibody ...

UK biotech Epsilogen has bought US-based TigaTx, pooling their resources to create what it says will be a leader in ...

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

Epsilogen completes acquisition of TigaTx to create world’s leading pan-isotype cancer antibody company: London Tuesday, April 8, 2025, 10:00 Hrs [IST] Epsilogen, the global lea ...

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...

UK-based developer of novel immunoglobulin E (IgE) antibodies to treat cancer, Epsilogen, says it has completed the ...

Learn about anaphylaxis, a severe allergic reaction, its symptoms, causes, diagnosis, treatment, prevention, and importance ...

The treatment of asthma and allergic rhinitis using unique, humanized anti-IgE monoclonal antibodies with very particular binding specificities is now supported by the results of multiple phase II ...